The week in pharma: action, reaction and insight – week to May 2

4 May 2025

By Barbara Obstoj-Cardwell. Editor

US biotech Biohaven last week received a commitment from Oberland Capital to invest up to $600 million in the company. Also, Regulus Therapeutics accepted a takeover bid from Swiss pharma giant Novartis worth a potential $1.7 billion. On the dealmaking front, US biotech Amicus Therapeutics acquired rights to Australian drug developer Dimerix’ kidney disease candidate DMX-200. Also of note, Eli Lilly had a setback, when the USA’s leading pharmacy benefits manager, CVS, said it will give Novo Nordisk’s weight loss product Wegovy priority over its Zepbound.

Positive with recent SCA and financing updates from Biohaven

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK